CYCLE-1
Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 27 patients (estimated)
- Sponsors
- Celyad Therapeutics
- Tags
- CAR T Cell, Chemotherapy, NKG2D
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1588
- NCT Identifier
- NCT04167696
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.